CRO services within obesity
Accelerate your drug development by exploring clinical endpoints in our
validated obese mouse models
Publications
- Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism
- Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
- Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control
- An optimized mouse brain atlas for automated mapping and quantification of neuronal activity using iDISCO+ and light sheet fluorescence microscopy
- Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development
Get in touch
Please get in touch if you are interested in discussing how to get started with your study. Reach out to Director Michael Feigh mfe@gubra.dk Ph. +45 2382 9493
Publications
- The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach
- Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development
- The imprinted gene neuronatin is regulated by metabolic status and associated with obesity
Publications
- Neuromedin U inhibits food intake partly by inhibiting gastric emptying
- Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control
- GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice
Gubra 3D Experience
To enable fast and efficient data mining of quantitative 3D imaging data, Gubra has developed a web-based 3D imaging data viewer (Gubra 3D Experience, G3DE). This resource provides researchers with a platform for exploring Gubra’s published 3D imaging data in further detail.
G3DE is particularly relevant in preclinical drug development for obesity. Click here to explore individual brain regions of interest, display quantitative c-Fos data and filter for regions with statistically significant response to drug treatment.
Download paper: Whole-brain activation signatures of weight-lowering drugs. Article and front cover of Molecular Metabolism (Vol 47 – May 2021).
Whole-brain imaging of drug distribution
Anti-obesity drugs may cross the blood-brain barrier to engage with appetite-regulating regions. Gubra uses 3D imaging to determine whole-brain distribution of fluorescently tagged therapeutic peptides and antibodies.
Download poster: Whole-brain distributional differences of lipidated Exendin-4 peptides
Download flyer: Whole-organ drug distribution
Types of studies
Acute efficacy studies
In an acute efficacy study we offer e.g.
- OGTT/IPGTT/IVGTT and ITT in rats and mice
- Automatized food intake testing
- Conditioned taste aversion testing
- In vitro biology
Chronic efficacy studies
In a chronic efficacy study we offer e.g.
- Body weight, food intake, food preference
- Chronic efficacy testing (7 days to 12+ weeks)
- EchoMRI determination of body fat and tissue fat (e.g. liver)
- Ex vivo assays (TG, Chol, FFAs, Hormones: Leptin, ghrelin, glucagon, insulin, GLP-1, GIP, PYY3-36 etc.)
Mode of action studies
In a mode of action study we offer e.g.
- EchoMRI
- Energy expenditure and metabolic cages
- Conditioned taste aversion and pica behavior
- Selective vagal deafferentation (SDA) and area postrema ablation
- Bariatric surgery
- Blood pressure
- c-Fos – a marker of neuronal activation
- CNS drug distribution
Gubra in vivo study approach in obesity
We conduct preclinical obesity studies in the vast majority of all commercially available rodent models.
Years of scientific and technical CRO expertise, combined with our constant animal availability and readiness, translate into speed and high scientific standards. We provide solid data and scientific guidance which you can use as the foundation for business decisions to move your projects forward.
Related Links:
Main offerings
- DIO models and the majority of commercially available models.
- Acute or chronic anorectic properties assessed in real-time food/water/activity monitoring system.
- Monitoring of food preference, taste aversion and pica behavior.
- Site-specific compound administration, e.g. intrathecal, intracerebroventricular or local injections into specific brain nuclei.
- Total body fat measurements using our EchoMRI scanner.
- Tissue fat measurements using small sample EchoMRI scanner.
- Energy expenditure testing using indirect calorimetry.
- In vivo lipogenesis.
- Selective vagal deafferentiation and other MoA validations.
- RNA sequencing and bioinformatics.
Get in touch
Please get in touch if you are interested in discussing how to get started with your study.
Michael Feigh
Director
mfe@gubra.dk
+45 2382 9493
